High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00154050

Enrollment

Registered

2005-09-12

Start date

2004-05-31

Completion date

2006-07-31

Last updated

2006-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Occlusive Diseases

Keywords

restenosis, intima hyperproliferation, stent angioplasty, pain-free walking distance

Brief summary

The study is designed to test the hypothesis that high dose candesartan treatment compared to quinapril is able to reduce intima hyperproliferation and the restenosis rate after stent angioplasty in peripheral occlusive artery disease.

Detailed description

Patients are randomly assigned to treatment with either candesartan 32 mg/d or Quinapril 20 mg/d before the angioplasty. Walking distance, intima media thickness and crurobrachial pressure ratios are compared after 6 weeks, 3 months and 6 months. After 6 months an angiographic control is performed.

Interventions

DRUGcandesartan (drug) or quinapril (drug)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* male and female * peripheral occlusive arterial disease Stad IIb Fontaine classification

Exclusion criteria

* patients with lesions not available for PTA * renal insufficiency * patients on calcium-antagonists

Design outcomes

Primary

Measure	Time frame
Restenosis/reintervention after 6 months	—

Secondary

Measure	Time frame
pain-free walking distance	—
crurobrachial pressure ratios	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026